The funding will go toward bringing the BA100 test to clinicians. The test can identify patients most likely to respond to the standard of care chemotherapy treatment.
Its tests use FTIR to measure the spectra from biochemical changes in peripheral blood mononuclear cells, along with a proprietary technique that analyzes results.
Genomic Health will gain exclusive worldwide rights to develop and sell an IVD version of its Oncotype DX breast cancer test on Biocartis' Idylla platform.
The group said that progress in developing the test for a broad range of medical conditions will be driven in part by frequent donations of urine samples.
